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Background: The mutation status of the BRAF and KRAS genes has been proposed as prognostic biomarker in
colorectal cancer. Of them, only the BRAF V600E mutation has been validated independently as prognostic for
overall survival and survival after relapse, while the prognostic value of KRAS mutation is still unclear. We
investigated the prognostic value of BRAF and KRAS mutations in various contexts defined by stratifications of the
patient population.
Methods: We retrospectively analyzed a cohort of patients with stage II and III colorectal cancer from the PETACC-3
clinical trial (N = 1,423), by assessing the prognostic value of the BRAF and KRAS mutations in subpopulations
defined by all possible combinations of the following clinico-pathological variables: T stage, N stage, tumor site,
tumor grade and microsatellite instability status. In each such subpopulation, the prognostic value was assessed by
log rank test for three endpoints: overall survival, relapse-free survival, and survival after relapse. The significance
level was set to 0.01 for Bonferroni-adjusted p-values, and a second threshold for a trend towards statistical
significance was set at 0.05 for unadjusted p-values. The significance of the interactions was tested by Wald test,
with significance level of 0.05.
Results: In stage II-III colorectal cancer, BRAF mutation was confirmed a marker of poor survival only in
subpopulations involving microsatellite stable and left-sided tumors, with higher effects than in the whole
population. There was no evidence for prognostic value in microsatellite instable or right-sided tumor groups. We
found that BRAF was also prognostic for relapse-free survival in some subpopulations. We found no evidence that
KRAS mutations had prognostic value, although a trend was observed in some stratifications. We also show
evidence of heterogeneity in survival of patients with BRAF V600E mutation.
Conclusions: The BRAF mutation represents an additional risk factor only in some subpopulations of colorectal
cancers, in others having limited prognostic value. However, in the subpopulations where it is prognostic, it
represents a marker of much higher risk than previously considered. KRAS mutation status does not seem to
represent a strong prognostic variable.
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Our current models of colorectal cancer (CRC) are domi-
nated by the idea of a sequential tumor progression from
adenoma to carcinoma, in which the accumulation of gen-
etic events in key genes defines alternative oncogenic
paths with impact on tumor characteristics. These genetic
events include the mutational activation of oncogenes like
BRAF and KRAS, disruption of WNT signaling, allelic im-
balance on chromosome 18q and mutation of TP53 tumor
suppressor gene [1-4]. Since the mutations of BRAF and
KRAS genes, which lead to the activation of MEK/ERK
pathway, are seen as important events in the tumor pro-
gression and based on their relatively high incidence (7-
15% for BRAF mutations and 35-40% for KRAS mutations
[5-8]), they have been proposed as prognostic biomarkers
for CRC. Of them, only BRAF V600E mutation has been
consistently validated, while the prognostic value of KRAS
mutation remains debatable. The BRAF has been shown
to be prognostic for overall survival (OS) and survival after
relapse (SAR) in general CRC population by us and others
[9-13] as well as in microsatellite-stable (MSS) population
[12,14], while having no prognostic value for relapse-free
survival (RFS). In these studies, the hazard ratios (HR) for
BRAF mutation varied between 1.4 and 2.1 for OS and 2.3
to 3.6 for SAR. In the case of KRAS mutation, the pub-
lished results are contradictory, with prognostic value, in
the positive studies, found only for relapse-free survival
[9,11,15], while other studies, including our own [13], did
not find any evidence of prognostic value for KRAS muta-
tion. Also, a recent meta-analytical review found no evi-
dence supporting the prognostic value of KRAS mutation
[16]. A detailed review is given in [17].
The question remains whether the prognostic value of
the BRAF and KRAS mutations is uniform across different
patient groups defined by clinical parameters or if there
are interactions that would influence their utility. Taking
advantage of a large series of stage II-III CRC tumors with
mutation data from the PETACC-3 clinical trial [18], we
systematically investigate the prognostic value of the
BRAF and KRAS mutations in all possible stratifications –
contexts – defined by a set of clinical parameters found to
be important in survival prognosis in a previous analysis
[19]. The main question our study tries to answer is
whether the mutations of BRAF and KRAS genes are indi-
cators of different prognosis within otherwise uniform
(with respect to the clinical parameters considered) sub-
populations of patients with CRC. A secondary question
we address, for the main findings, is whether the observed
prognostic values are statistically significant also in multi-
variate models, in the respective subpopulations.
Methods
We retrospectively analyzed the PETACC-3 clinical trial
[18] data set (N = 1,423), of patients with stage II and IIICRC, by generating the subpopulations defined by all
possible combinations of levels of the following five vari-
ables: MSI status (MSI-H and MSS levels), tumor site (left
and right), T stage (T1,2, T3, and T4), N stage (N0, N1
and N2) and tumor grade (G1,2 and G3,4). In total, there
were 393 possible subpopulations (see Additional file 1 for
an exhaustive listing), of which only those with more than
N = 20 samples were further considered for testing the
prognostic value of the BRAF and KRAS mutations. The
full description of the data set is given in [19].
In each subpopulation, the prognostic importance of the
BRAF and KRAS mutations was assessed using log-rank
test comparing the survival of BRAF-/KRAS-mutant
population to the BRAF- and KRAS- wild type (double
wild type – WT2) population, for overall survival (OS),
relapse-free survival (RFS) and survival after relapse (SAR)
endpoints. Data was summarized with hazard ratios (HR),
their 95% confidence intervals (CI), P-values and adjusted
P-values (Bonferonni correction, denoted hereinafter
by P*). For a result to be considered statistically signifi-
cant we required that P* ≤ 0.01 and that at least 10
patients were in each of the two groups compared. If
only P ≤ 0.05, the result was reported as a trend towards
significance. The significance of the interactions was tested
by Wald test in the presence of both main effects, with
significance level of 0.05 (no adjustment for multiple test-
ing in this case). All tests were two-sided.
All computations were carried out in R version 2.15.2
(http://www.r-project.org) and survival analysis was performed
using R survival package version 2.37-2.
Results and discussion
In the global population, the BRAF mutation is prognostic
for poorer overall survival and survival after relapse, while
KRAS mutation is not prognostic for any of the three end-
points (Table 1). In stratified analyses and after correction
for multiple testing, BRAF mutation status remained a
significant prognostic marker in various subpopulations.
On the contrary, KRAS mutation status never reached the
level of significance required after P-value adjustment
(P* ≤ 0.01 and at least 10 patients in both of the groups
compared). However, in several stratifications, KRAS
mutation showed a trend towards significance (P ≤ 0.05).
The full table of results with all possible stratifications is
given as Additional file 1.
BRAF mutation
The BRAF mutation was prognostic for overall survival in
MSS and/or left-sided tumors subpopulations (Figure 1).
In the MSS tumors, BRAF was indicative of worse overall
survival (P* < 0.0001; HR = 2.82; 95% CI = 1.85 to 4.30), as
well as in MSS/left tumors (P* < 0.0001; HR = 6.41; 95%
CI = 3.57 to 11.52) and all left-sided tumors (P* < 0.0001;
HR = 5.18; 95% CI = 3.00 to 8.94) (Figure 1A,B). At the
Table 1 Univariate analysis of the prognostic factors in the whole CRC population
OS RFS SAR
Factor Comparison P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI)
MSI MSI-H vs MSS 0.0002 0.45 (0.30,0.69) < 0.0001 0.48 (0.34,0.68) 0.9643 0.99 (0.65,1.52)
Site Left vs Right 0.3143 0.89 (0.72,1.11) 0.2123 1.13 (0.93,1.36) <0.0001 0.59 (0.47, 0.73)
Grade G3,4 vs G1,2 0.0018 1.63 (1.29,2.23) 0.0012 1.56 (1.19,2.04) 0.0387 1.38 (1.01,1.88)
T stage T3 vs T1,2 0.0634 1.76 (0.96,3.22) 0.0629 1.58 (0.97,2.58) 0.1399 1.57 (0.86,2.88)
T4 vs T1,2 0.0002 3.06 (1.63,5.74) < 0.0001 2.69 (1.61,4.48) 0.0680 1.78 (0.95,3.35)
N stage N1 vs N0 < 0.0001 1.91 (1.38,2.65) < 0.0001 1.78 (1.36, 2.32) 0.9809 0.98 (0.71,1.35)
N2 vs N0 < 0.0001 4.51 (3.28,6.21) < 0.0001 4.06 (3.11,5.29) 0.1498 1.24 (0.90,1.71)
BRAF BRAF mut vs WT2 0.0004 1.92 (1.33,2.78) 0.0832 1.35 (0.96,1.89) < 0.0001 2.56 (1.75,3.70)
BRAF mut vs BRAF wt 0.0009 1.78 (1.26,2.53) 0.1174 1.30 (0.94,1.81) < 0.0001 2.48 (1.74,3.53)
KRAS KRAS mut vs WT2 0.1461 1.20 (0.93,1.54) 0.4410 1.09 (0.88,1.33) 0.1755 1.18 (0.93,1.52)
KRAS mut vs KRAS wt 0.4826 1.09 (0.86,1.37) 0.7245 1.04 (0.85,1.27) 0.7222 1.04 (0.82,1.32)
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stratification involving only right-sided tumors (Figure 1C)
and/or MSI-H tumors. In a multivariate model, including
up to second degree interactions between MSI status,
BRAF mutation and tumor site, adjusted for grade, T stage
and N stage, the only significant interaction was between
BRAF mutation and tumor site (P = 0.0041). The inter-
action between BRAF mutation status and tumor site was
also significant within MSS tumors (P = 0.0033), but not
within MSI-H tumors. The interaction between BRAF
mutation status and MSI status was not significant in
either left or right-sided tumors. These results show that
BRAF mutation represents an additional risk factor only
within MSS/left tumors, with no statistically significant
effect in right or MSI-H tumors, the general prognostic
value of BRAF mutation being driven by its effect in this
subpopulation. As a consequence, the corresponding HR
should be re-interpreted: a BRAF mutation does not
double the risk of death for all patients carrying thisFigure 1 Overall survival: prognostic value of BRAF and KRAS mutatio
sided tumors; C: MSS right-sided tumors. The light gray survival curve repre
C: MSS right-sided tumors).mutation (HR = 1.92 in global population), but represents
a six-fold increase of the risk in the case of patients with
MSS/left tumors (HR = 6.41) – in comparison with the
double wild type MSS/left tumors. At the same time,
BRAF mutation does not significantly influence the risk of
death (in comparison with WT2) in MSI-H and/or right-
sided tumors. The MSS/left side BRAF-mutant population
emerges as the worst surviving group of patients in our
data set: for example, the 3-year overall survival rate is
0.35 (95% CI = 0.20 to 0.66) in comparison to 0.89
(95% CI = 0.85 to 0.93) for KRAS-mutant and 0.91
(95% CI = 0.88 to 0.93) for WT2, respectively (Table 2).
The observation could not be extended to MSS/right-
sided tumors (Table 2).
Interestingly, BRAF mutation was also prognostic for
shorter relapse-free survival in left-sided tumors (Figure 2):
all left-sided tumors (P* = 0.0002; HR = 3.31; 95% CI = 1.98
to 5.55) and MSS/left tumors (P* = 0.0005; HR = 3.57;
95% CI = 2.02 to 6.31) (Figure 2, see also Table 2). Thisns within MSS and by tumor site. A: all MSS tumors; B: MSS left-
sents the whole subpopulation survival (A: all MSS, B: MSS left-sided,
Table 2 Three-year overall and relapse-free survival rates,
and one-year survival after relapse rates in MSS/left and
MSS/right populations, stratified by mutation status
MSS/left MSS/right
Population Survival rate 95% CI Survival rate 95% CI
OS: 3-year survival rates
WT2 0.91 0.88-0.93 0.83 0.77-0.89
KRAS mut 0.89 0.85-0.93 0.80 0.74-0.86
BRAF mut 0.37 0.20-0.66 0.73 0.60-0.89
RFS: 3-year survival rates
WT2 0.75 0.71-0.80 0.75 0.68-0.82
KRAS mut 0.68 0.62-0.74 0.73 0.66-0.80
BRAF mut 0.32 0.16-0.61 0.68 0.54-0.84
SAR: 1-year survival rates
WT2 0.81 0.74-0.88 0.65 0.52-0.82
KRAS mut 0.80 0.71-0.89 0.75 0.53-0.80
BRAF mut 0.17 0.05-0.60 0.36 0.17-0.79
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generally considered prognostic for relapse. In other
MSS-subpopulations involving left-sided tumors BRAF
mutation is also prognostic (see Additional file 1).
Again, the BRAF mutation was not prognostic in any
subpopulation involving MSI-H and/or right-sided tu-
mors. In a multivariate model, involving up to second
degree interactions between MSI status, BRAF mutation
and tumor site, adjusted for grade, T stage and N stage,
the only significant interaction was between BRAF
mutation and tumor site (P = 0.047). The interaction
between BRAF mutation status and tumor site was also
significant within MSS tumors (P = 0.043), but not within
MSI-H tumors (where the small number of BRAF mutants
in the left colon limits the statistical power). Hence, theFigure 2 Relapse-free survival: prognostic value of BRAF and KRAS in
The light gray survival curve represents the whole subpopulation survival (Aprognostic value of the BRAF mutation is confined to the
MSS/left-sided tumors.
For the survival after relapse (SAR), BRAF mutation rep-
resents an additional risk factor in more stratifications,
most of them involving MSS and/or left-sided tumors.
BRAF mutation shows also a trend to be prognostic in
MSS/right-sided tumors as well, even though the p-value
was no longer significant after multiple testing correction.
The BRAF mutation was indicative of poor survival
after relapse in all MSS tumors (P* < 0.0001; HR = 3.43;
95% CI = 2.19 to 5.36); MSS/left tumors (P* = 0.0002;
HR = 3.89; 95% CI = 2.11 to 7.20) and showed a trend in
MSS/right (P = 0.0111; HR = 2.27; 95% CI = 1.17 to 4.38)
(Figure 3). The test for interaction between BRAF muta-
tion status and tumor site was not significant, hence we
conclude that BRAF mutation is prognostic for SAR in
all MSS patients.
The differences in prognostic value of the BRAF mu-
tation status in various subpopulations suggest a certain
degree of heterogeneity in the survival of patients har-
boring this mutation. Indeed, within the BRAF mutant
population, the MSS tumors had worse outcome for
overall survival (P = 0.0021; HR = 3.45; 95% CI = 1.49 to
7.69)) and relapse-free survival (P = 0.0085; HR = 2.63;
95% CI = 1.25 to 5.56), this observation being in line
with the fact that MSI-H has a protective prognostic effect
in CRC. At the same time, the left BRAF-mutant tumors
had a worse prognosis than the right BRAF-mutant
tumors, for overall survival (within all BRAF-mutants:
P = 0.0003; HR = 3.20; 95% CI = 1.64 to 6.23; within MSS/
BRAF-mutants: P = 0.0059; HR = 2.84; 95% CI = 1.31 to
6.15; while within MSI-H/BRAF-mutants it could not be
assessed) and for relapse-free survival (within all BRAF-
mutants: P = 0.0002; HR = 3.24; 95% CI = 1.71 to 6.16;
within MSS/BRAF-mutants: P = 0.0062; HR = 2.82; 95%left-sided tumors. A: all left-sided tumors; B: MSS left-sided tumors.
: all left tumors; B: MSS left).
Figure 3 Survival after relapse: prognostic value of BRAF and KRAS mutations in MSS tumors by site. A: all MSS tumors; B: MSS left-sided
tumors; C: MSS right-sided tumors. The light gray survival curve represents the whole subpopulation survival (A: all MSS, B: MSS left-sided, C: MSS
right-sided tumors).
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could not be assessed). However, there was no statistically
significant difference in survival after relapse among BRAF
mutants, all having an equally poor survival.
KRAS mutation
KRAS mutation did not reach the significance level
required to be considered prognostic for any of the three
endpoints, since the adjusted p-values were all larger than
0.01. However, in some cases, it showed a trend towards
significance (P ≤ 0.05).
In overall survival, KRAS mutation had a trend to be-
come significant in several stratifications of tumors with
early stage lymph node invasion (N1). In all these, KRAS
mutation was a marker of worse outcome (see Additional
file 1). While not being a significant prognostic factor (as
required by us) for relapse-free survival, KRAS mutationFigure 4 Relapse-free survival: prognostic value of BRAF and KRAS in
tumors; C: MSI-H right-sided tumors. The light gray survival curve represent
C: MSI-H right-sided tumors).showed a trend to become prognostic. In contrast with
BRAF, KRAS mutation seemed to be prognostic for RFS
mostly in the right colon. The most intriguing observation
was in MSI-H/right colon subpopulation (N = 102, KRAS
mutants: 39), where KRAS mutation seemed to identify
a low risk group (P = 0.0349; HR = 0.29; 95% CI = 0.08
to 0.99) (Figure 4). KRAS mutation was not prognostic
for SAR. Also, no significant interaction between KRAS
mutation, MSI status and tumor site was observed, for
any of the three endpoints.
Since several studies have suggested that KRAS muta-
tions at codon 12 may have a different prognostic value
than codon 13 mutations [20], we have tested for differ-
ences in survival between the two groups of mutations,
in all the same stratifications. No statistically significant
difference was observed, but the sample size of our data
might be too limited to detect such differences.MSI-H tumors by site. A: all MSI-H tumors; B: MSI-H left-sided
s the whole subpopulation survival (A: all MSI-H, B: MSI-H left-sided,
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In our analyses, we have compared the survival of BRAF/
KRAS-mutated population with that of the double-wild
type population, while controlling for several other param-
eters (tumor site, T and N stage, grade and MSI status).
Our analyses confirm the prognostic value of BRAF
mutation status, in various stratifications. As a novelty,
we observe a strong prognostic value for relapse-free
survival of the BRAF mutation status in the MSS/left-
colon tumors.
The interpretation of BRAF mutation as additional
risk factor has to be made in the context of MSI status
and tumor location. Indeed, our results show that BRAF
represents a risk factor in the left colon and/or MSS
tumors. In the data analyzed, we found no sufficient
statistical evidence supporting a worse outcome associ-
ated with BRAF mutation in MSI-H tumors. As a conse-
quence, the published hazard ratios for BRAF mutation
for general population have to be reconsidered. The tumor
staging (T or N stage, tumor grade) had a lesser impact on
the prognostic value of the BRAF mutation status, while
the tumor background (site and microsatellite (in)stability)
significantly influenced the prognostic.
For the KRAS mutation, we could not confirm nor com-
pletely disprove its prognostic value. It was prognostic in
several stratifications, in some showing a protective effect,
while in others representing a risk factor. This is probably
an effect of the heterogeneity of KRAS mutant population
[21,22] and may explain in part the contradictory results
published so far. With the strict requirements for statis-
tical significance imposed, KRAS mutation did not appear
to have prognostic value in any of the stratifications. The
trend towards significance suggests, however, a potential
utility as prognostic marker for RFS mostly in right colon.
In conclusion, the utility of the BRAF and KRAS as
prognostic biomarkers depends on the MSI status and
tumor location. We hypothesize that this interaction
may extend to other biomarkers and prognostic gene
signatures as well. At the same time, this observation
has clear implications in clinical trial design and needs
to be accounted for.
We make public the full table with all stratifications to
support similar analyses in other data sets.Additional file
Additional file 1: Full survival analysis results. In each possible
stratification three endpoints were tested - overall survival, relapse-free
survival and survival after relapse - and the sample size of the analysis
along with the resulting p-values and hazard ratios are given.Abbreviations
MSI: Microsatellite instability; MSI-H: High microsatellite instability;
MSS: Microsatellite stable; OS: Overall survival; RFS: Relapse-free survival;SAR: Survival after relapse; WT2: Double wild type tumors: tumors that are
BRAF- and KRAS-wild type.
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